ReviewFrontiers in immunology2021
Gut Microbiota Dysbiosis in Systemic Lupus Erythematosus: Novel Insights into Mechanisms and Promising Therapeutic Strategies.
Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 98 citations in OpenAlex.
- Probiotics in Autoimmune Disease: Strain-specific Mechanisms and Therapeutic Perspectives.Clinical reviews in allergy & immunology · 2026Review
- Gut metaproteomics reveals activated arginine catabolism and impaired arginine biosynthesis in systemic lupus erythematosus.mSystems · 2026Article
- Intestinal and Blood-Brain Barrier Dysfunction in Lupus: Emerging Mechanisms and Modulation by Cinnamon.Molecules (Basel, Switzerland) · 2026Review
- From pathogenesis to precision medicine in systemic lupus erythematosus: Emerging biomarkers and targeted interventions.iScience · 2026Review
- Integrative Approaches to Gut Microbiota: Biomarkers, Dysbiosis, and Therapeutic Potential.Saudi medical journal · 2026Review
- Allergic reactions in systemic lupus erythematosus: From pathogenic pathways to clinical practice.Asia Pacific allergy · 2026Review
- Neuropsychiatric systemic lupus erythematosus - current and novel treatments.Current opinion in rheumatology · 2026Review
- SCARF1 deficiency exacerbates gut inflammation and autoimmune pathology.Scientific reports · 2026Article
- Gut dysbiosis in a murine model of cutaneous lupus erythematosus correlates with antigen-specific T cells and antigen-presenting cells in skin.Scientific reports · 2026Article
- The microbiota-systemic lupus erythematosus axis: mechanisms, diagnostics, and therapeutic frontiers.Frontiers in immunology · 2026Review
- Bacterial Extracellular Vesicles in Aging: Mechanisms and Therapeutic Prospects.International journal of nanomedicine · 2026Review
- Exploring the Role of Skin Microbiota in Autoimmune Skin Diseases from a Bidirectional Mendelian Randomization Perspective.Clinical, cosmetic and investigational dermatology · 2026Article
- Immunopathogenesis and Therapeutics of Systemic Lupus Erythematosus: an Integrative Review.Clinical reviews in allergy & immunology · 2025Review
- Gut Microbiome and Immune System Crosstalk in Chronic Inflammatory Diseases: A Narrative Review of Mechanisms and Therapeutic Opportunities.Microorganisms · 2025Review
- Gut microbiota and metabolism in systemic lupus erythematosus: from dysbiosis to targeted interventions.European journal of medical research · 2025Review
- The Anti-Lupus Plate: Mapping Nutritional Interventions to Inflammatory Pathways in Systemic Lupus Erythematosus.Food science & nutrition · 2025Review
- Unveiling Molecular Mechanisms Underlying Obesity-Associated Systemic Lupus Erythematosus.Endocrinology, diabetes & metabolism · 2025Review
- Pharmacological insights into gut microbiota modulation in systemic lupus erythematosus: Mechanisms, treatment strategies, and clinical implications.The Journal of pharmacology and experimental therapeutics · 2025Review
- Extracellular Vesicles Derived From Streptococcus anginosus Aggravate Lupus Nephritis by Triggering TLR2-MyD88-NF-κB Signalling in NK Cells.Journal of extracellular vesicles · 2025Article
- Gut-vitamin D interplay: key to mitigating immunosenescence and promoting healthy ageing.Immunity & ageing : I & A · 2025Review
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that was traditionally thought to be closely related to genetic and environmental risk factors. Although treatment options for SLE with hormones, immunosuppressants, and biologic drugs are now available, the rates of clinical response and functional remission of these drugs are still not satisfactory. Currently, emerging evidence suggests that gut microbiota dysbiosis may play crucial roles in the occurrence and development of SLE, and manipulation of targeting the gut microbiota holds great promises for the successful treatment of SLE. The possible mechanisms of gut microbiota dysbiosis in SLE have not yet been well identified to date, although they may include molecular mimicry, impaired intestinal barrier function and leaky gut, bacterial biofilms, intestinal specific pathogen infection, gender bias, intestinal epithelial cells autophagy, and extracellular vesicles and microRNAs. Potential therapies for modulating gut microbiota in SLE include oral antibiotic therapy, fecal microbiota transplantation, glucocorticoid therapy, regulation of intestinal epithelial cells autophagy, extracellular vesicle-derived miRNA therapy, mesenchymal stem cell therapy, and vaccination. This review summarizes novel insights into the mechanisms of microbiota dysbiosis in SLE and promising therapeutic strategies, which may help improve our understanding of the pathogenesis of SLE and provide novel therapies for SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.